In fact, tumor-bearing mice treated with AT38 ([3-(aminocarbonyl) furoxan-4-yl] methyl salicylate), an ARG1 and iNOS transcriptional inhibitor, displayed a strong reduction of nitro-tyrosine (NTy)-based PTMs in tumor microenvironment favoring T-cell infiltration inside the tumor and improving anti-tumor immunotherapy (73). Here, ARG1 is linked to neoplasm.